ArticleInternational journal of molecular and cellular medicine2022
ACE-2 Expression and Methylation Pattern in Bronchoalveolar Lavage Fluid and Bloods of Iranian ARDS Covid-19 Patients.
Article in International journal of molecular and cellular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Methylation-Associated Differentiation Features Define Biological and Prognostic Heterogeneity in CMS4 Colorectal Cancer.International journal of molecular sciences · 2026Article
- Pioglitazone mitigates acetic acid-induced colitis in rats via epigenetic-modulation and antioxidant mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- SLC7A11 Inhibitors Represent a Promising Therapeutic Target by Facilitating the Induction of Ferroptosis in Breast Cancer.International journal of molecular and cellular medicine · 2025Review
- Pulmonary toxoplasmosis in a multiple myeloma patient: A Case report and literature review.International journal of molecular and cellular medicine · 2025Article
- DNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19.Microorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the expression and methylation pattern of the angiotensin I converting enzyme 2 (ACE-2) in acute respiratory distress syndrome (ARDS) covid-9 patients. A total of 25 patients with covid-19 ARDS and 20 controls were recruited. Expression of the ACE-2 gene was evaluated by quantitative real time PCR, and methylation of CpG dinucleotides, in the ACE-2 promoter, was quantified using bisulfite pyro-sequencing. Our results showed high expression of the ACE-2 gene in the blood samples of ADRS patients (1.93± 0.67) in comparison to controls (0.62±0.35) (P = 0.03). Correspondingly, in ARDS bronchoalveolar lavage fluid (BALF) samples, there was a high expression of this gene (1.8±0.78) in comparison to controls (0.58±0.2) (p <0.05). Moreover, the methylation rate of the ACE-2 gene in blood samples of ARDS patients was 64.07 ±6.1 in comparison to controls (80.3 ±7.3) (p<0.0001). In BALF samples, there was this pattern too (55.07 ±3.1 vs. 72.35±5.1) (p<0.0001). Finally, a significant correlation was found between expression and methylation in BALF (R= -0.54, P= 0.002) and blood (R= -0.321, P= 0.013) samples. These results indicated that aberrant methylation of the ACE-2 promoter might be associated with high expression of this gene and the occurrence of ARDS in covid-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.